Physician profile

Rommel Rivera

Psychiatry · Philadelphia, PA

NPI 1619098159

$11,931.30

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$130.14

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $11,475.82 2019-2021
Abbvie INC. $130.14 2023 Vraylar
Tactile Systems Technology INC $79.73 2019
Janssen Pharmaceuticals, INC $72.40 2019-2020
Alkermes, INC. $69.26 2019-2020
Teva Pharmaceuticals USA, INC. $53.88 2019
Sunovion Pharmaceuticals INC. $38.99 2019-2020
Allergan, INC. $11.08 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rommel Rivera

$11,931.30

in general payments reported 2019-2025

Years
2019-2023
Top company
Otsuka America Pharmaceutical, INC.

https://glasscript.com/doctor/164097/rommel-rivera

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.